ASTRAZENECA SP ADR (ZEGA MU) stock market data APIs
€77.874
0(0%)
as of December 19, 2025
Try our APIs with
free plan!
ASTRAZENECA SP ADR Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ZEGA.MU.
Prev. Close
77.874
Open
77.874
High
77.874
Low
77.874
52 wk Range
58.5906-80.5
Market Cap
148 612 M
Dividends (Yield)
0.0227
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ASTRAZENECA SP ADR data using free add-ons & libraries
Get ASTRAZENECA SP ADR Fundamental Data
ASTRAZENECA SP ADR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ASTRAZENECA SP ADR News
New
Is It Too Late To Consider AstraZeneca After Its Strong 2025 Share Price Rally?
For anyone wondering whether AstraZeneca is still worth considering after its big run or whether the best days are already priced in, this article will walk through what the numbers are really saying ...
Syneron Bio Closes Nearly $100M in Series A and A+ Rounds
BEIJING, Dec. 18, 2025 /PRNewswire/ -- Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully completed its Series A and A+ financi...
Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies
Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca 10-year supply agreement will help advance new radioconjugate therapies capable of precis...
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this p...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
